NPS CEO: Shire has rare-disease experience
NPS Pharmaceuticals president and CEO Dr. Francois Nader discusses opportunities the potential deal with Shire presents.
Anyone who follows Jim Cramer’s stock picks knows that he loves the biotech sector. Especially NPS Pharmaceuticals, up 45 percent in the past month. Wowzer!On Sunday, Ireland-based Shire PLC agreed to acquire NPS Pharma for an all cash deal of […]
Rumor has it that if the S&P 500 finishes its first five trading days of the year with a gain, then the year in question will — 80 percent of the time — end with a gain as well.Last Thursday’s rally gave the S&P that five-day gain. However, since that day, the market has seen a decent amount of weakness.The […]
In recent years, there have been many bad times in which to be long biotechnology stocks and exchange traded funds, but with some marquee industry conferences imminent, the biotech industry is in the midst of one of its most potent seasonal periods.December is the second-best month of the year for the broader biotech sector after July, but due to the […]
Source: GlaxoSmithKline via Flickr.When it comes to healthcare events, there is none more important than the JPMorgan Healthcare Conference. Filled with dozens upon dozens of biotech and medical device companies, the JPMorgan Healthcare Conference, coming up in mid-January, is the perfect time for companies to unveil a study or device they’ve been keeping under their thumb for a rainy day.With […]
View gallery.The graphs below were produced by Capital Market Labs.A critical factor in assessing pharmaceutical and biotech companies is the quality of their drug pipelines. This is especially true as investors begin to look at the smaller companies in the space; the smaller the company, the more an investment is simply a bet on that particular pipeline.So, let’s take a look […]
The bull market is nearing six years old. It turns out that the biotech sector again managed a huge outperforming year in 2014 as well. The gains of the key biotech exchange traded funds (ETFs) were up in the 40% range, with the NYSE Arca Biotech index up over 45% year-to-date. The equal-weight biotech ETF performed better than the key larger […]
View gallery.This week brings to close yet another year of gains for the stock market, the sixth straight year in this bull run.The benchmark S&P 500 started off 2014 at 1848 and as of Friday the index sat at 2088.Some of the top industries of the year include airlines, semiconductors, hospitals, aluminum, Internet service providers and residential REITs.Another industry cracking this […]
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk, low-growth biotech stocks that investors might consider avoiding: Inovio Pharmaceuticals , VIVUS , and Zogenix .Inovio Pharmaceuticals At first glance, […]
NASDAQ had a good surge last week, but now people are honestly wondering what’s next. It had a nice pop at the open yesterday,, but immediately headed south and stayed there for the rest of the session. The bad news was that there was no enthusiasm for buying, but the good news was that there was no real selling after […]
Benchmarks settled in the green for the fourth-straight session boosted by gains made by large-cap technology stocks. The S&P 500 closed at a record level for the 50th time in 2014, its highest number of record closings in a year since 1995. The Dow too posted a record close for the 35th time this year. Gains in technology shares offset […]
